Wangying

Dr. WANG YING has dedicated the career to the research and development of therapeutics for pan-metabolic diseases. Holding a PhD in Biology from Nanjing University, Dr. WANG YING specializes in elucidating the intricate pathological mechanisms underlying complex diseases, such as mental disorders and diabetes. With a commitment to this field, Dr. WANG YING has leveraged the advanced framework of metabolomics technology to explore these complex conditions in recent years, paving the way for innovative diagnostic and therapeutic approaches.

 Unveiling Synergistic Potency: Exploring Butyrolactone I to Enhance Gentamicin Efficacy against Methicillin-Resistant Staphylococcus aureus (MRSA) Strain USA300-Published in ACS Infectious Diseases, 2024.

 A Novel Phenazine Analog, CPUL1, Suppresses Autophagic Flux and Proliferation in Hepatocellular Carcinoma: Insight from Integrated Transcriptomic and Metabolomic Analysis- Published in Cancers, 2023.

Efficient Discovery and Creation of Marine Microbial Drug Candidates (National Key Research and Development Program “Deep-sea Key Technologies and Equipment”).